about
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapyAcadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II studyRituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trialHigh microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.Radiological features of non-gastric mucosa-associated lymphoid tissue lymphomas.Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapyStratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.Targeting prohibitins induces apoptosis in acute myeloid leukemia cells.Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group.Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.CD 30-positive transformed follicular lymphoma: two case reports and literature review.AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment.Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era.Low-Dose PET/CT and Full-Dose Contrast-Enhanced CT at the Initial Staging of Localized Diffuse Large B-Cell Lymphomas.Langerhans cell sarcoma: Response to radiotherapy.European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis.Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.[Positron emission tomography combined with computed tomography in the initial evaluation and response assessment in primary central nervous system lymphoma].Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype.HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry.Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy.
P50
Q28307991-1900BFAC-6EC6-4D8B-8240-C3FE89698614Q33404763-013E957B-AA2A-4C91-AFE1-80BB5649687CQ33410917-FF53CC73-B04D-4863-BD0C-D92565B7985DQ33828585-D08D97AE-7061-42F1-A1DF-021D01784341Q33828620-D48C6CA0-2BC7-42C8-B036-B304D91E9BB4Q35082512-C83FC7AF-B15B-4B84-B306-B2F391C7296CQ35906053-A83726B3-89D7-47B9-A816-5FCFC7063B08Q36962906-504D681D-6305-4349-9056-C7D958492BB6Q37109671-043BA106-D76A-4D2E-9355-1B8A72AE55C7Q37212700-2C6ADF51-1149-41F1-A2B3-3EB02A433063Q37618909-C1A480C8-FDD3-49EC-9DBD-4B4B02EA3D0DQ37662175-7230CAC0-CAB9-4B47-AD0E-3B053436812EQ38110232-572359E5-C1AC-45B3-92DE-4D533DFF0AB4Q38234470-2A851274-59A1-428E-9D75-3A4B656AE0F3Q38466350-67200F69-B874-4FB5-8A4C-CF5556CEFF23Q39674990-6C4B13D8-0125-4315-91C0-582F05EC6BEEQ40022297-6FDF9DC6-A934-42A9-A06B-6E825DE92CCAQ40316913-1ED5B77B-88C6-4D50-99C4-11A0FA5861A9Q40671200-B27E184B-B769-466A-807E-74C1148DFE8DQ40785301-D0789FF9-3380-4BFA-82D2-08721119DF70Q41114153-B16FB2D4-8E9D-4DC1-9BDE-9337E946FC69Q41456094-9E7BCD76-EEB5-45EC-A203-27B831F7ADB5Q41665481-BEE23901-3370-4F8D-B492-3D3855FF91ECQ41978699-23A38901-A17D-4347-ADD3-93C1EF23D746Q42388539-5A5381E0-BEDA-4993-9145-D8F3589CC9CCQ42759159-5FAB5BCD-4125-4FEF-817E-939B7F81260CQ43286767-74FD5F3D-6D6A-49BA-B1BC-43C7EC633FFCQ43454344-05C8C093-2084-426D-8B70-100E2CFE904FQ44100215-77066B65-EC9F-4277-B192-9BCA61638CC9Q44114704-0CF6902A-DA3C-49DB-8811-A228D935D7C8Q44170509-AA8E767B-C585-4036-AA79-894487A21A2AQ45398095-63530CF1-3E39-4C73-9085-59958AADF79BQ46302136-69A8CA03-81D2-4803-9AB8-2C30236C63D7Q46318984-67BE44D3-AB6C-4D1C-9340-B4683409710EQ46500135-97D8790A-B53B-4033-AD04-325632430DA9Q47948560-3E65170D-594E-4902-93BD-BB0FDE7C99AFQ51851505-14BE3DAC-3B79-4AF8-84AD-DADB034D2865Q52929584-AF2C8B87-A046-4336-B852-3AA4AAF3CF29Q53099332-0D595822-40E0-4F16-8D64-D63E27511CA5Q53110830-5CFAC9E7-9B22-498A-BD1E-0F20F063FDC5
P50
description
researcher
@en
wetenschapper
@nl
name
Eva Gonzalez-Barca
@en
Eva Gonzalez-Barca
@nl
type
label
Eva Gonzalez-Barca
@en
Eva Gonzalez-Barca
@nl
prefLabel
Eva Gonzalez-Barca
@en
Eva Gonzalez-Barca
@nl
P106
P31
P496
0000-0002-1323-1508